BUSINESS● LOWOct 8 · Oct 8, 2026, 10:51 AM
Argenx falls after ending late-stage trial for Sjögren's disease therapy
Seeking Alpha Tech · global
Argenx's stock declined following the termination of a late-stage clinical trial for its Sjögren's disease therapy. This event affects the company's pharmaceutical development pipeline and market valuation.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS47m ago‘Hot economics, cold politics’: why China gave nod for expanded Japanese trade tripSouth China Morning PostBUSINESS48m agoOntario gas prices this weekend : GTA forecastcambridgetimes.ca · Canada